Today: 8 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Polestar stock drops despite “best year ever” sales; Feb. 18 update is next test

Polestar stock drops despite “best year ever” sales; Feb. 18 update is next test

Polestar shares fell 5.9% to $20.90 in Friday’s Nasdaq session after the company reported preliminary 2025 retail sales of about 60,119 cars, up 34%, and a 27% rise in fourth-quarter volumes. The company said a December ADS ratio change restored compliance with Nasdaq’s $1 bid-price rule. CEO Michael Lohscheller set Feb. 18 for a strategy update. Europe now accounts for 78% of sales as U.S. tariffs and competition weigh.
9 January 2026
··
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers shares dropped 5.3% to $32.06 after Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill. Bank of America cut its price target on Hims, citing margin and spending risks for 2026. The stock fell from an intraday high of $34.35. Investors are watching for signs of pricing pressure and updated forecasts ahead of Hims’ next earnings report.
9 January 2026
··
Las Vegas Sands stock slides as Macau margin jitters flare — what investors are watching next

Las Vegas Sands stock slides as Macau margin jitters flare — what investors are watching next

Las Vegas Sands shares fell 4.3% to $59.25 Friday afternoon, underperforming a rising U.S. market. Analysts cited concerns over Macau operating costs and fourth-quarter margins after Sands China and Melco Resorts dropped sharply in Hong Kong. Other casino stocks with Macau exposure also declined. Investors are watching for the company’s next results update later this month.
9 January 2026
·
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
9 January 2026
···
Intuitive Machines (LUNR) stock slides after Stifel downgrade as NASA moon rover decision nears

Intuitive Machines (LUNR) stock slides after Stifel downgrade as NASA moon rover decision nears

Intuitive Machines shares fell 3.8% to $18.88 Friday after Stifel downgraded the stock to “hold,” citing uncertainty over a pending NASA rover contract. The stock swung between $17.82 and $19.73 on heavy volume. NASA’s Lunar Terrain Vehicle award remains undecided. Investors are also watching for U.S. inflation data on Jan. 13 and company earnings on March 19.
9 January 2026
··
Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Equity Residential shares fell 3.8% to $60.46 after BMO Capital downgraded the stock, citing softening rental markets in major coastal cities. The drop followed news of a $400 million sale of three properties to JRK Property Holdings. Other large apartment REITs also traded lower. Investors are watching for upcoming U.S. inflation data and Equity Residential’s earnings on Feb. 2.
9 January 2026
···
Valero (VLO) stock slides as Venezuela oil talks loom and an analyst trims a target

Valero (VLO) stock slides as Venezuela oil talks loom and an analyst trims a target

Valero shares dropped 3.2% to $185.16 Friday afternoon, underperforming other refiners as the White House met with oil firms, including Valero and Marathon, to discuss possible investment in Venezuela. Piper Sandler cut its Valero price target to $217. Oil prices rose amid global supply concerns. Investors await Valero’s Jan. 29 earnings report for margin and policy updates.
9 January 2026
·····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Why Abercrombie & Fitch stock is sliding today despite a UBS target hike

Why Abercrombie & Fitch stock is sliding today despite a UBS target hike

Abercrombie & Fitch shares dropped 3.7% to $125.09 Friday after a weaker U.S. jobs report and mixed consumer sentiment data. UBS raised its price target on the stock to $160, citing expected 2026 earnings growth. Payrolls rose by 50,000 in December, with job losses in retail. Investors await the Fed’s Jan. 27-28 meeting and Abercrombie’s next results, expected in early March.
9 January 2026
·
HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity shares dropped 2.9% to $95.64 Friday after Goldman Sachs downgraded the stock to sell and set an $89 target. The move followed HealthEquity’s raised fiscal 2026 revenue outlook and a report of $34.4 billion in HSA assets. KeyBanc maintained an Overweight rating and lifted its price target to $125. The stock fell as the S&P 500 and Nasdaq 100 rose.
9 January 2026
···
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio shares fell 4.7% to $8.05 Friday afternoon, underperforming biotech peers. UBS began coverage at Neutral with a $10 target, while RBC raised its target to $9 and reiterated Outperform. CEO David Hung is set to present at the J.P. Morgan Healthcare Conference on Jan. 13. Investors await early March results for updates on IBTROZI’s launch and pipeline spending.
9 January 2026
·
1 … 217 218 219 220 221 … 535

Stock Market Today

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

8 February 2026
New York, Feb 7, 2026, 17:35 EST — Market closed. Abbott Laboratories (ABT) shares rose 1.6% to $110.83 on Friday, extending a second straight day of gains. It trailed a broader rally in which the S&P 500 climbed 1.97% and the Dow gained 2.47%, and it remains 21.53% below its 52-week high of $141.23, with 9.9 million shares changing hands versus a 50-day average of 8.9 million. (MarketWatch) U.S. markets are shut on Saturday, leaving investors a weekend to focus on regulation rather than price action. The Food and Drug Administration updated a Class I recall notice — its most
Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

8 February 2026
Verizon shares fell 1.7% to $46.31 on Friday, ending a seven-day rally and lagging a broad market rebound. The drop follows a leadership shakeup in the consumer unit, with Sowmyanarayan Sampath stepping down and Alfonso Villanueva named interim chief. Investors await delayed U.S. jobs and inflation data next week, which could affect rate-sensitive stocks.
Go toTop